



EUROPEAN ASSOCIATION OF
PHARMA BIOTECHNOLOGY

European Association of Pharma Biotechnology
Europäische Arbeitsgemeinschaft für Pharma Biotechnologie
Association Européenne de Pharma Biotechnologie

Press release: Regenerative Medicine Special Interest Group of EAPB

Date: June 1, 2010

EAPB's Special Interest Group on "Regenerative Medicine" will meet in Hannover

In combination with the biotech trade fair Biotechnica the European Association of Pharma Biotechnology – EAPB - holds its next workshop of regenerative medicine on October 4, 2010

Advanced Therapy Medicinal Products (ATMPs) are tightly regulated by the European Medicines Agency (EMA) with the intention to ensure the safety, efficacy as well as the good quality of the products. A well defined risk evaluation in order to cover the whole development process and not only quality or safety risks should be set-up. For example, tumorigenicity, genome stability, biodistribution are now among the top issues during non-clinical and clinical development and need to be addressed for stem cell-based products early. A key point is hereby an efficient communication with the regulators as early as possible to avoid detours or even worst failures. So the scientific advice became a very powerful tool to find the right way through the jungle of guidelines, reflection papers, regulations and the expectation of the regulators.

The aim of this workshop is to bring together experts on regulation and developers from academia and industry in order to share experiences and handy tips for the process of scientific advice by regulatory agencies and for the development of cell-based products in Europe.

Presentations will be about the significance of scientific advice for small enterprises and the dos and don'ts during the process of scientific advice as well as quality standards of stem cell based therapies.

Detailed program with titles and speakers will be published during July 2010.

Registration will be open starting July 2010.

Location: Biotechnica, Conference Centre Hannover Messe

Time: October 4, 2010, 1:30 – 5:30 pm

Registration fee:

150,- € for non-members

50,- € for existing members of SIG "Regenerative Medicine"

President: Wieland W. Wolf, PhD
1st Vice: Karoline Bechthold-Peters, PhD
2nd Vice: Axel Wenzel, PhD
<http://www.eapb.org>

Managing Director
Marion Kronabel, PhD
mobile +49 151 543 615 22
Mail to: marion.kronabel@eapb.org



EUROPEAN ASSOCIATION OF
PHARMA BIOTECHNOLOGY

European Association of Pharma Biotechnology
Europäische Arbeitsgemeinschaft für Pharma Biotechnologie
Association Européenne de Pharma Biotechnologie

The European Association of Pharma Biotechnology (EAPB) is the representative of pharmaceutical biotechnology in Europe and dedicated to the advancement of biotechnology in pharmaceutical sciences, specifically as applied to medicinal drugs, industrial materials, processes, products and their associated issues.

As a non-profit organization EAPB provides a central network linking academia, industry and regulatory bodies. Accordingly its members are professionals from biotechnology and pharmaceutical companies, governmental authorities, academia and scientific organizations.

Events organized by EAPB promote collaborations between science and industry in the sector of pharmaceutical biotechnology. Specifically the technology transfer focused Science to Market Conferences intent to enhance the economical output of scientific research and direct them into marketable technologies and biopharmaceutical products.

For further information please visit www.eapb.org or contact:

Dr. Marion Kronabel (Managing Director)
c/o
Heidelberg Technology Park, Campus Office
Im Neuenheimer Feld 582
69120 Heidelberg
Phone +49 6221 3 89 39 85
Fax +49 6221 3 89 37 68
E-mail: marion.kronabel@eapb.org

President: Wieland W. Wolf, PhD
1st Vice: Karoline Bechthold-Peters, PhD
2nd Vice: Axel Wenzel, PhD
<http://www.eapb.org>

Managing Director
Marion Kronabel, PhD
mobile +49 151 543 615 22
Mail to: marion.kronabel@eapb.org